A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age
Sponsor: ModernaTX, Inc.
Listed as NCT06602024, this PHASE3 trial focuses on Seasonal Influenza and remains completed. Sponsored by ModernaTX, Inc., it has been updated 7 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .